The relationship between changes in mood state and the report of personality disorder symptoms was examined in a sample of 44 outpatients. Subjects completed a battery of self-report inventories and a semistructured interview on two occasions separated by 6 months. Although significant changes in depression and anxiety were observed over time, personality disorder scores from self-report inventories and the interview were relatively stable over time. Further, changes in depression and anxiety scores were not significantly related to changes in personality disorder scores. Results suggest that self-report personality disorder scores may be as reliable as those derived from semistructured interviews.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1207/s15327752jpa6101_7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
High fatigue levels among psychiatric outpatients - the validity of the Danish Patient Reported Outcomes Measurement Information System Fatigue Short-Form (PROMISF-SF).
J Patient Rep Outcomes
January 2025
Department of Clinical Medicine, Faculty of Health, University of Copenhagen, Copenhagen, Denmark.
Background: Patient Reported Outcomes Measurement Information System Fatigue Short-Form (PROMIS-F-SF) is a self-administered, patient reported outcome (PRO) designed to assess fatigue in healthy and clinical populations and for tracking progress during treatment for disorders complicated with fatigue.
Methods: Patients in the Mental Health Service Outpatient Clinics and healthy volunteers were invited to complete a survey, which included the Danish translation of the PROMIS-F-SF, the Chalder Fatigue Scale (CFS-11), and measures of depression and anxiety. We conducted a confirmatory factor analysis of the previously suggested single-factor structure of the instrument.
Borderline in a linear city: Urban living brings borderline personality disorder to crisis through neuroplasticity-an urgent call to action.
Front Psychiatry
January 2025
Department of Architecture, University of Cambridge, Cambridge, United Kingdom.
Suggestions for the decision making in subjective cognitive complaints.
Aging Clin Exp Res
January 2025
Dipartimento di Psicologia dello Sviluppo e della Socializzazione, Università di Padova, Padova, Italy.
In recent years, the increasing life expectancy has underscored the importance of cognitive health alongside physical well-being, particularly because healthy adults may report subjective cognitive complaints (SCC), often related to memory. These complaints may or may not align with objective cognitive impairments, fueling ongoing debates about whether SCC could serve as an early indicator of dementia. While some studies suggest SCC as a potential precursor to dementia, others propose that these complaints may merely co-occur with cognitive decline.
View Article and Find Full Text PDFThe psychometric properties of the Thai version of the Zuckerman-Kuhlman-Aluja personality questionnaire.
Sci Rep
January 2025
Centre of Specialist Postgraduate Programmes in Psychology, Institute of Psychology, Károli Gáspár University of the Reformed Church, Budapest, 1037, Hungary.
The Five-Factor Model of personality traits has consistently demonstrated expected associations with features of psychiatric disorders, both within the general population and clinical settings. In pursuit of a more nuanced understanding, facet-level assessments like the Zuckerman-Kuhlman-Aluja Personality Questionnaire (ZKA-PQ) offer more profound insights into their facets. However, notably, the applicability of the ZKA-PQ to the Thai population remains untested.
View Article and Find Full Text PDFEfficacy and Safety of BI 1358894 in Patients With Borderline Personality Disorder: Results of a Phase 2 Randomized, Placebo-Controlled, Parallel Group Dose-Ranging Trial.
J Clin Psychiatry
January 2025
Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York.
To provide proof-of-concept (PoC), dose-range finding, and safety data for BI 1358894, a TRPC4/5 ion channel inhibitor, in patients with borderline personality disorder (BPD). This was a phase 2, multinational, randomized, double-blind, placebo controlled trial. Patients were randomized to oral placebo or BI 1358894 (5 mg, 25 mg, 75 mg, or 125 mg) once daily in a 2.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!